Clinical Trials | January 12, 2026
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Subscribe To Our Newsletter & Stay Updated
